Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

Study Overview
=================
Brief Summary
-----------------
The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies

Detailed Description
-----------------
Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets. This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.

Official Title
-----------------
Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

Conditions
-----------------
Non-Infectious Active Uveitis

Intervention / Treatment
-----------------
* Other: s-CD95-L


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of non-infectious uveitis according to the SUN (Standardization of the Uveitis Nomenclature) working Group; Age ≥ 18 years; being affiliated to health insurance, willing to participate. Exclusion Criteria: Pregnant or breastfeeding women, patient under legal protection measure , poor understanding of the French language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Biological samples<br>levels of s-CD95-L (ELISA test) | Other: s-CD95-L<br>* levels of s-CD95-L (ELISA test)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| levels of s-CD95-L | levels of s-CD95-L (ELISA test) in sera of non-infectious uveitis patients | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between levels of s-CD95-L and Disease activity score | Correlation between levels of s-CD95-L and Disease activity score (as defined by ophthalmologic examination) | Baseline, Month 3 | 
| Th17 dosage | Th17 dosage | Baseline, Month 3 | 
| polynuclear neutrophils levels | polynuclear neutrophils levels (Flow cytometry) | Baseline, Month 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non infectious active uveitis, Soluble-CD95-Ligand